A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics
The use of hydroxychloroquine therapy for the treatment of Covid-19 is controversial. In this study, Lyngbakken and colleagues present a randomized controlled trial and show that the drug has no antiviral effects in humans infected with SARS-CoV-2.
Main Authors: | Magnus Nakrem Lyngbakken, Jan-Erik Berdal, Arne Eskesen, Dag Kvale, Inge Christoffer Olsen, Corina Silvia Rueegg, Anbjørg Rangberg, Christine Monceyron Jonassen, Torbjørn Omland, Helge Røsjø, Olav Dalgard |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-10-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-020-19056-6 |
Similar Items
-
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial
by: Magnus Nakrem Lyngbakken, et al.
Published: (2020-06-01) -
Molecular analysis and epidemiological typing of Vancomycin-resistant Enterococcus outbreak strains
by: Anbjørg Rangberg, et al.
Published: (2019-08-01) -
Circulating microRNAs and aerobic fitness--the HUNT-Study.
by: Anja Bye, et al.
Published: (2013-01-01) -
Plasma Trans Fatty Acid Levels, Cardiovascular Risk Factors and Lifestyle: Results from the Akershus Cardiac Examination 1950 Study
by: Anupam Chandra, et al.
Published: (2020-05-01) -
Diagnostic and Prognostic Properties of Osteoprotegerin in Patients with Acute Dyspnoea: Observations from the Akershus Cardiac Examination (ACE) 2 Study.
by: Ragnhild Røysland, et al.
Published: (2016-01-01)